Reaction Details |
| Report a problem with these data |
Target | Mitogen-activated protein kinase 14 |
---|
Ligand | BDBM50099331 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_817829 (CHEMBL2027477) |
---|
Ki | 60±n/a nM |
---|
Citation | Duffy, JP; Harrington, EM; Salituro, FG; Cochran, JE; Green, J; Gao, H; Bemis, GW; Evindar, G; Galullo, VP; Ford, PJ; Germann, UA; Wilson, KP; Bellon, SF; Chen, G; Taslimi, P; Jones, P; Huang, C; Pazhanisamy, S; Wang, YM; Murcko, MA; Su, MS The Discovery of VX-745: A Novel and Selective p38a Kinase Inhibitor. ACS Med Chem Lett2:758-763 (2011) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Mitogen-activated protein kinase 14 |
---|
Name: | Mitogen-activated protein kinase 14 |
Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta |
Type: | Serine/threonine-protein kinase |
Mol. Mass.: | 41286.76 |
Organism: | Homo sapiens (Human) |
Description: | Q16539 |
Residue: | 360 |
Sequence: | MSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQ
SIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQ
KLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMT
GYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVG
TPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAA
QALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES
|
|
|
BDBM50099331 |
---|
n/a |
---|
Name | BDBM50099331 |
Synonyms: | 4-(4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl)pyridine | 4-[5-(4-Fluoro-phenyl)-3-piperidin-4-yl-3H-imidazol-4-yl]-pyridine | CHEMBL279416 | VK-19911 |
Type | Small organic molecule |
Emp. Form. | C19H19FN4 |
Mol. Mass. | 322.3794 |
SMILES | Fc1ccc(cc1)-c1ncn(C2CCNCC2)c1-c1ccncc1 |
Structure |
|